PDL BioPharma, Inc.[PDLI] stock saw a move by -5.06% on Thursday, touching 1.7 million. Based on the recent volume, PDL BioPharma, Inc. stock traders appear to be active. The most recent trading volume of PDLI shares recorded 117.29M shares, which represents the daily volume of traded shares. Analysts estimates state that PDL BioPharma, Inc. [PDLI] stock could reach median target price of $3.00.

PDL BioPharma, Inc. [PDLI] stock additionally went up by +1.36% in the period of the 7 days, recording a drop in performance by -12.55% in the last 30 days. The yearly more of PDLI stock is set at 0.00% by far, with shares price recording returns by -20.47% in the latest quarter. Over the past six months, PDLI shares showcased -31.90% decrease. PDLI saw -42.16% change opposing the low price in the last 12 months, also recording 1.81% compared to high within the same period of time.

PDL BioPharma, Inc. [NASDAQ:PDLI]: Analyst Rating and Earnings

Its stock price has been found in the range of 2.21 to 3.89. This is compared to its latest closing price of $2.37.

Keep looking out for the next-scheduled quarterly financial results that this company is expected to put out, which is slated to occur on Tue 5 Nov (In 53 Days).

Fundamental Analysis of PDL BioPharma, Inc. [PDLI]

Now let’s turn to look at profitability: with a current Operating Margin for PDL BioPharma, Inc. [PDLI] sitting at +34.48 and its Gross Margin at +67.55, this company’s Net Margin is now 34.10%. These measurements indicate that PDL BioPharma, Inc. [PDLI] is generating considerably more profit, after expenses are accounted for, compared to its market peers.

This company’s Return on Total Capital is 7.03, and its Return on Invested Capital has reached -7.40%. Its Return on Equity is -8.74, and its Return on Assets is -6.24. These metrics suggest that this PDL BioPharma, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, PDL BioPharma, Inc. [PDLI] has generated a Total Debt to Total Equity ratio of 17.08. Similarly, its Total Debt to Total Capital is 14.59, while its Total Debt to Total Assets stands at 12.93. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 5.62, and its Long-Term Debt to Total Capital is 17.08.

What about valuation? This company’s Enterprise Value to EBITDA is -0.13 and its Total Debt to EBITDA Value is 1.48. The Enterprise Value to Sales for this firm is now -0.08, and its Total Debt to Enterprise Value stands at 0.82.

Shifting the focus to workforce efficiency, PDL BioPharma, Inc. [PDLI] earns $1,886,762 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 2.30 and its Total Asset Turnover is 0.18. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 9.50 and its Current Ratio is 9.86. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

PDL BioPharma, Inc. [PDLI] has 117.29M shares outstanding, amounting to a total market cap of $277.98M. Its stock price has been found in the range of 2.21 to 3.89. At its current price, it has moved down by -42.16% from its 52-week high, and it has moved up 1.81% from its 52-week low.

This stock’s Beta value is currently 0.65, which indicates that it is 4.51% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 33.49. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is PDL BioPharma, Inc. [PDLI] a Reliable Buy?

Shares of PDL BioPharma, Inc. [PDLI], overall, appear to be a solid investment option, with Wall Street analysts expecting its price to rise considerably in the next 12 months. This company generates high value from the labor resources and other capital it has available, and while it has heavy Long-Term Debt to Equity, the majority of the metrics point to this investment being highly attractive.